尿激酶型纖溶酶原激活物受體（uPAR）是一種糖基磷脂酰肌醇錨定的膜蛋白，已被發(fā)現(xiàn)在多種癌細(xì)胞中過表達(dá)，這一特性使得uPAR成為治療癌癥的一個(gè)理想靶標(biāo)。目前，多種以u(píng)PAR為靶點(diǎn)的抗癌藥物已被開發(fā)，主要包括多肽、單克隆抗體、配體靶向毒素。此外，uPAR作為靶點(diǎn)也已在納米藥物遞送系統(tǒng)和光熱療法（PTT）/光動(dòng)力療法（PDT）中得到應(yīng)用。因此就靶向uPAR的抗腫瘤藥物的研究進(jìn)展做一綜述。

Urokinase-type plasminogen activator receptor (uPAR) is a glycosyl phosphatidyl inositol-anchored membrane protein which has been found to be over-expressed in a variety of cancer cells, and this property makes uPAR a promising candidate for cancer treatment. At present, a variety of anti-tumor drugs targeting uPAR have been developed, mainly including peptides, monoclonal antibodies, and ligand-targeted toxins. In addition, uPAR has also been used as a target in nano-drug delivery systems and photothermal therapy (PTT)/photodynamic therapy (PDT). Therefore, this paper reviews the research progress of anti-tumor drugs targeting uPAR.

R979.1

陜西省教育廳重點(diǎn)科研計(jì)劃項(xiàng)目（21JS009）；陜西省科技廳自然科學(xué)基礎(chǔ)研究計(jì)劃項(xiàng)目（2022JQ-932）；西安市衛(wèi)生健康委員會(huì)項(xiàng)目（SZY202103）